Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs

PLoS Pathogens

Volumn 13, Issue 9, 2017, Pages

  Tartour, Kevin ^a,b,c,d,e,f   Nguyen, Xuan Nhi ^a,b,c,d,e,f   Appourchaux, Romain ^a,b,c,d,e,f   Assil, Sonia ^a,b,c,d,e,f   Barateau, Véronique ^a,b,c,d,e,f   Bloyet, Louis Marie ^a,b,c,d,e,f   Burlaud Gaillard, Julien ^g   Confort, Marie Pierre ^c   Escudero Perez, Beatriz ^a,b,c,d,e,f   Gruffat, Henri ^a,b,c,d,e,f   Hong, Saw See ^c   Moroso, Marie ^{a,b,c,d,e,f,h}   Reynard, Olivier ^a,b,c,d,e,f   Reynard, Stéphanie ^{a,b,c,d,e,f,i}   Decembre, Elodie ^a,b,c,d,e,f   Ftaich, Najate ^c   Rossi, Axel ^a,b,c,d,e,f   Wu, Nannan ^{a,b,c,d,e,f,j}   Arnaud, Frédérick ^c   Baize, Sylvain ^{a,b,c,d,e,f,i}   Dreux, Marlène ^a,b,c,d,e,f   Gerlier, Denis ^a,b,c,d,e,f   Paranhos Baccala, Glaucia ^{a,b,c,d,e,f,h}   Volchkov, Viktor ^a,b,c,d,e,f   Roingeard, Philippe ^g   Cimarelli, Andrea ^a,b,c,d,e,f   more..

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ DE LYON   (France)

^g UNIVERSITÉ DE TOURS   (France)

^h Fondation Mérieux Applied Research   (France)

ⁱ INSTITUT PASTEUR   (France)

^j EAST CHINA NORMAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD45 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR5; INTERFERON INDUCED TRANSMEMBRANE PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN;

ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; VIRION; VIRUS PURIFICATION; VIRUS REPLICATION; CELL LINE; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; VIRUS ENTRY;

ANTIGENS, DIFFERENTIATION; CELL LINE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 85030466977     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006610     Document Type: Article

References (92)

1. Bailey CC, Kondur HR, Huang IC, Farzan M, Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem. 2013;288(45):32184–93. Epub 2013/09/27. doi: 10.1074/jbc.M113.514356 24067232.
2. Weston S, Czieso S, White IJ, Smith SE, Kellam P, Marsh M, A membrane topology model for human interferon inducible transmembrane protein 1. PLoS One. 2014;9(8):e104341. Epub 2014/08/12. doi: 10.1371/journal.pone.0104341 25105503.
3. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR, Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell. 1984;38(3):745–55. 6548414.
4. Farber CR, Reich A, Barnes AM, Becerra P, Rauch F, Cabral WA, et al. A Novel IFITM5 Mutation in Severe Atypical Osteogenesis Imperfecta Type VI Impairs Osteoblast Production of Pigment Epithelium-Derived Factor. J Bone Miner Res. 2014. Epub 2014/02/13. doi: 10.1002/jbmr.2173 24519609.
5. Kasaai B, Gaumond MH, Moffatt P, Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation. J Biol Chem. 2013;288(19):13278–94. Epub 2013/03/27. doi: 10.1074/jbc.M113.457010 23530031.
6. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139(7):1243–54. Epub 2010/01/13. doi: 10.1016/j.cell.2009.12.017 20064371.
7. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484(7395):519–23. Epub 2012/03/27. doi: 10.1038/nature10921 22446628.
8. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7(1):e1001258. Epub 2011/01/22. doi: 10.1371/journal.ppat.1001258 21253575.
9. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C, The IFITM proteins inhibit HIV-1 infection. J Virol. 2011;85(5):2126–37. Epub 2010/12/24. doi: 10.1128/JVI.01531-10 21177806.
10. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481–5. Epub 2011/04/12. doi: 10.1038/nature09907 21478870.
11. Perreira JM, Chin CR, Feeley EM, Brass AL, IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol. 2013;425(24):4937–55. Epub 2013/10/01. doi: 10.1016/j.jmb.2013.09.024 24076421.
12. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol. 2013;87(15):8451–64. Epub 2013/05/31. doi: 10.1128/JVI.03382-12 23720721.
13. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, et al. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One. 2013;8(11):e80723. Epub 2013/11/28. doi: 10.1371/journal.pone.0080723 24278312.
14. Anafu AA, Bowen CH, Chin CR, Brass AL, Holm GH, Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem. 2013;288(24):17261–71. Epub 2013/05/08. doi: 10.1074/jbc.M112.438515 23649619.
15. Bailey CC, Huang IC, Kam C, Farzan M, Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012;8(9):e1002909. Epub 2012/09/13. doi: 10.1371/journal.ppat.1002909 22969429.
16. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013;87(14):7837–52. Epub 2013/05/10. doi: 10.1128/JVI.00481-13 23658454.
17. Zhang W, Zhang L, Zan Y, Du N, Yang Y, Tien P, Human respiratory syncytial virus infection is inhibited by IFN-induced transmembrane proteins. J Gen Virol. 2015;96(Pt 1):170–82. doi: 10.1099/vir.0.066555-0 25228491.
18. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology. 2014;11:103. doi: 10.1186/s12977-014-0103-y 25422070.
19. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe. 2014;16(6):736–47. doi: 10.1016/j.chom.2014.11.001 25464829.
20. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol. 2012;86(24):13697–707. Epub 2012/10/12. doi: 10.1128/JVI.01828-12 23055554.
21. Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, et al. The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. J Biol Chem. 2015;290(43):25946–59. doi: 10.1074/jbc.M115.657346 26354436.
22. Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, et al. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. Cell Rep. 2015;13(1):145–56. doi: 10.1016/j.celrep.2015.08.055 26387945.
23. Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, et al. Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. Cell Host Microbe. 2016;20(4):429–42. doi: 10.1016/j.chom.2016.08.006 27640936.
24. Weston S, Czieso S, White IJ, Smith SE, Wash RS, Diaz-Soria C, et al. Alphavirus Restriction by IFITM Proteins. Traffic. 2016;17(9):997–1013. doi: 10.1111/tra.12416 27219333.
25. Munoz-Moreno R, Cuesta-Geijo MA, Martinez-Romero C, Barrado-Gil L, Galindo I, Garcia-Sastre A, et al. Antiviral Role of IFITM Proteins in African Swine Fever Virus Infection. PLoS One. 2016;11(4):e0154366. doi: 10.1371/journal.pone.0154366 27116236.
26. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, et al. The IFITMs Inhibit Zika Virus Replication. Cell Rep. 2016;15(11):2323–30. doi: 10.1016/j.celrep.2016.05.074 27268505.
27. Gorman MJ, Poddar S, Farzan M, Diamond MS, The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis. J Virol. 2016;90(18):8212–25. doi: 10.1128/JVI.00581-16 27384652.
28. Poddar S, Hyde JL, Gorman MJ, Farzan M, Diamond MS, The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses. J Virol. 2016;90(19):8780–94. doi: 10.1128/JVI.00655-16 27440901.
29. Wilkins J, Zheng YM, Yu J, Liang C, Liu SL, Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV. PLoS One. 2016;11(6):e0156739. doi: 10.1371/journal.pone.0156739 27257969.
30. Qian J, Le Duff Y, Wang Y, Pan Q, Ding S, Zheng YM, et al. Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology. 2015;474:10–8. doi: 10.1016/j.virol.2014.10.015 25463599.
31. Wrensch F, Hoffmann M, Gartner S, Nehlmeier I, Winkler M, Pohlmann S, Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins. J Virol. 2017;91(2). doi: 10.1128/JVI.01488-16 27807233.
32. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT, Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol. 2010;84(24):12646–57. doi: 10.1128/JVI.01328-10 20943977.
33. Warren CJ, Griffin LM, Little AS, Huang IC, Farzan M, Pyeon D, The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One. 2014;9(5):e96579. Epub 2014/05/16. doi: 10.1371/journal.pone.0096579 24827144.
34. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 2013;5(4):895–908. Epub 2013/11/26. doi: 10.1016/j.celrep.2013.10.033 24268777.
35. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013;9(1):e1003124. Epub 2013/01/30. doi: 10.1371/journal.ppat.1003124 23358889.
36. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol. 2014. Epub 2014/02/14. doi: 10.1111/cmi.12262 24521078.
37. Chesarino NM, McMichael TM, Hach JC, Yount JS, Phosphorylation of the Antiviral Protein IFITM3 Dually Regulates its Endocytosis and Ubiquitination. J Biol Chem. 2014. Epub 2014/03/15. doi: 10.1074/jbc.M114.557694 24627473.
38. Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, et al. pH-optimum of hemagglutinin-mediated membrane fusion determines sensitivity of influenza A viruses to the interferon-induced antiviral state and IFITMs. J Virol. 2017. doi: 10.1128/JVI.00246-17 28356532.
39. Desai TM, Marin M, Mason C, Melikyan GB, pH regulation in early endosomes and interferon-inducible transmembrane proteins control avian retrovirus fusion. J Biol Chem. 2017. doi: 10.1074/jbc.M117.783878 28341742.
40. Plemper RK, Cell entry of enveloped viruses. Curr Opin Virol. 2011;1(2):92–100. Epub 2011/09/20. doi: 10.1016/j.coviro.2011.06.002 21927634.
41. Baquero E, Albertini AA, Vachette P, Lepault J, Bressanelli S, Gaudin Y, Intermediate conformations during viral fusion glycoprotein structural transition. Curr Opin Virol. 2013;3(2):143–50. Epub 2013/04/09. doi: 10.1016/j.coviro.2013.03.006 23562213.
42. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB, HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell. 2009;137(3):433–44. Epub 2009/05/05. doi: 10.1016/j.cell.2009.02.046 19410541.
43. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB, IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014;10(4):e1004048. Epub 2014/04/05. doi: 10.1371/journal.ppat.1004048 24699674.
44. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe. 2013;13(4):452–64. Epub 2013/04/23. doi: 10.1016/j.chom.2013.03.006 23601107.
45. Wrensch F, Winkler M, Pohlmann S, IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses. 2014;6(9):3683–98. doi: 10.3390/v6093683 25256397.
46. Fu B, Wang L, Li S, Dorf ME, ZMPSTE24 defends against influenza and other pathogenic viruses. J Exp Med. 2017. doi: 10.1084/jem.20161270 28246125.
47. Wang Y, Pan Q, Ding S, Wang Z, Yu J, Finzi A, et al. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. J Virol. 2017;91(7). doi: 10.1128/JVI.02441-16 28100616.
48. Wu WL, Grotefend CR, Tsai MT, Wang YL, Radic V, Eoh H, et al. Delta20 IFITM2 differentially restricts X4 and R5 HIV-1. Proc Natl Acad Sci U S A. 2017;114(27):7112–7. doi: 10.1073/pnas.1619640114 28630320.
49. Gruffat H, Manet E, Sergeant A, MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 2002;3(2):141–6. doi: 10.1093/embo-reports/kvf031 11818339.
50. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A. 1989;86(23):9524–8. 2556716.
51. Strobel B, Miller FD, Rist W, Lamla T, Comparative Analysis of Cesium Chloride- and Iodixanol-Based Purification of Recombinant Adeno-Associated Viral Vectors for Preclinical Applications. Hum Gene Ther Methods. 2015;26(4):147–57. doi: 10.1089/hgtb.2015.051 26222983.
52. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe. 2012;12(4):558–70. doi: 10.1016/j.chom.2012.08.010 23084922.
53. Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep. 2016;17(11):1657–71. doi: 10.15252/embr.201642771 27601221.
54. Xie M, Xuan B, Shan J, Pan D, Sun Y, Shan Z, et al. Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment. J Virol. 2015;89(6):3049–61. doi: 10.1128/JVI.03416-14 25552713.
55. Zhu X, He Z, Yuan J, Wen W, Huang X, Hu Y, et al. IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection. Cell Microbiol. 2014. Epub 2014/08/19. doi: 10.1111/cmi.12339 25131332.
56. Rhee SS, Hunter E, A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell. 1990;63(1):77–86. 2170021.
57. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107(1):55–65. 11595185.
58. Langelier C, von Schwedler UK, Fisher RD, De Domenico I, White PL, Hill CP, et al. Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release. J Virol. 2006;80(19):9465–80. doi: 10.1128/JVI.01049-06 16973552.
59. Ott DE, Purification of HIV-1 virions by subtilisin digestion or CD45 immunoaffinity depletion for biochemical studies. Methods Mol Biol. 2009;485:15–25. Epub 2008/11/21. doi: 10.1007/978-1-59745-170-3_2 19020815.
60. Bartosch B, Cosset FL, Studying HCV cell entry with HCV pseudoparticles (HCVpp). Methods Mol Biol. 2009;510:279–93. doi: 10.1007/978-1-59745-394-3_21 19009269.
61. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105(21):7552–7. doi: 10.1073/pnas.0802203105 18490657.
62. Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A. 2014. doi: 10.1073/pnas.1320856111 24753610.
63. Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat Chem Biol. 2010;6(8):610–4. Epub 2010/07/06. doi: 10.1038/nchembio.405 20601941.
64. Ding S, Pan Q, Liu SL, Liang C, HIV-1 mutates to evade IFITM1 restriction. Virology. 2014;454–455:11–24. Epub 2014/04/15. doi: 10.1016/j.virol.2014.01.020 24725927.
65. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol. 2006;80(22):11082–93. doi: 10.1128/JVI.01307-06 16956932.
66. Tatsuo H, Ono N, Tanaka K, Yanagi Y, The cellular receptor for measles virus: SLAM (CDw 150)]. Uirusu. 2000;50(2):289–96. 11276818.
67. Clavel F, Charneau P, Fusion from without directed by human immunodeficiency virus particles. J Virol. 1994;68(2):1179–85. 8289347.
68. Berlioz C, Darlix JL, An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors. J Virol. 1995;69(4):2214–22. 7884868.
69. Giraudon P, Jacquier MF, Wild TF, Antigenic analysis of African measles virus field isolates: identification and localisation of one conserved and two variable epitope sites on the NP protein. Virus Res. 1988;10(2–3):137–52. 2457995.
70. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE, Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol. 2009;83(18):9596–601. doi: 10.1128/JVI.00784-09 19587051.
71. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA, Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol. 2000;74(19):9281–93. 10982375.
72. Bartosch B, Dubuisson J, Cosset FL, Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197(5):633–42. doi: 10.1084/jem.20021756 12615904.
73. Follenzi A, Naldini L, Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 2002;346:454–65. 11883085.
74. Mangeot PE, Duperrier K, Negre D, Boson B, Rigal D, Cosset FL, et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther. 2002;5(3):283–90. doi: 10.1006/mthe.2002.0541 11863418.
75. Jarrosson-Wuilleme L, Goujon C, Bernaud J, Rigal D, Darlix JL, Cimarelli A, Transduction of nondividing human macrophages with gammaretrovirus-derived vectors. J Virol. 2006;80(3):1152–9. doi: 10.1128/JVI.80.3.1152-1159.2006 16414992.
76. Wang GZ, Goff SP, Postentry restriction of Mason-Pfizer monkey virus in mouse cells. J Virol. 2015;89(5):2813–9. doi: 10.1128/JVI.03051-14 25540373.
77. Grimm D, Kay MA, Kleinschmidt JA, Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther. 2003;7(6):839–50. 12788658.
78. Pierson TC, Diamond MS, Ahmed AA, Valentine LE, Davis CW, Samuel MA, et al. An infectious West Nile virus that expresses a GFP reporter gene. Virology. 2005;334(1):28–40. doi: 10.1016/j.virol.2005.01.021 15749120.
79. Ostertag D, Hoblitzell-Ostertag TM, Perrault J, Cell-type-specific growth restriction of vesicular stomatitis virus polR mutants is linked to defective viral polymerase function. J Virol. 2007;81(2):492–502. doi: 10.1128/JVI.01217-06 17065214.
80. Devaux P, Cattaneo R, Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. J Virol. 2004;78(21):11632–40. doi: 10.1128/JVI.78.21.11632-11640.2004 15479804.
81. Martinez MJ, Biedenkopf N, Volchkova V, Hartlieb B, Alazard-Dany N, Reynard O, et al. Role of Ebola virus VP30 in transcription reinitiation. J Virol. 2008;82(24):12569–73. doi: 10.1128/JVI.01395-08 18829754.
82. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125(6):1808–17. 14724833.
83. Bridgen A, Dalrymple DA, Elliott RM, Dugbe nairovirus S segment: correction of published sequence and comparison of five isolates. Virology. 2002;294(2):364–71. doi: 10.1006/viro.2001.1324 12009878.
84. Caplen H, Peters CJ, Bishop DH, Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol. 1985;66 (Pt 10):2271–7. doi: 10.1099/0022-1317-66-10-2271 4045430.
85. Wulff H, McIntosh BM, Hamner DB, Johnson KM, Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull World Health Organ. 1977;55(4):441–4. 304387.
86. Freed EO, Englund G, Martin MA, Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol. 1995;69(6):3949–54. 7745752.
87. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G, Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol. 2005;86(Pt 5):1455–65. doi: 10.1099/vir.0.80788-0 15831958.
88. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A, With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 2006;13(12):991–4. doi: 10.1038/sj.gt.3302753 16525481.
89. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology. 2007;4:2. doi: 10.1186/1742-4690-4-2 17212817.
90. Berger G, Durand S, Goujon C, Nguyen XN, Cordeil S, Darlix JL, et al. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc. 2011;6(6):806–16. doi: 10.1038/nprot.2011.327 21637200.
91. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–7. doi: 10.1038/nature10117 21613998.
92. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–61. doi: 10.1038/nature10195 21720370.